Sivextro approved for adult skin infections
(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.
Jun 23, 2014
0
0
(HealthDay)—The antibiotic Sivextro (tedizolid phosphate) has been approved by the U.S. Food and Drug Administration to treat adults with skin infections.
Jun 23, 2014
0
0
Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered the exact mode of action by plerixafor, a drug commonly prescribed to stimulate immune responses in patients suffering from neutropenia, which causes ...
Nov 14, 2013
0
0
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer and neutropenia who ...
Jan 30, 2013
0
0
(HealthDay)—The American Society of Clinical Oncology has issued updated recommendations for both the prevention and management of febrile episodes in neutropenic oncology outpatients; the recommendations have been published ...
Jan 15, 2013
0
0
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to ...
Nov 19, 2012
0
0
(HealthDay)—New evidence-based guidelines have been compiled on the management of fever and and neutropenia (FN) in children with cancer and/or who are undergoing hematopoietic stem-cell transplantation; the guidelines ...
Sep 19, 2012
0
0
Cancer chemotherapy can be a life-saver, but it is fraught with severe side effects, among them an increased risk of infection. Until now, the major criterion for assessing this risk has been the blood cell count: if the ...
Sep 12, 2012
0
0
(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.
Aug 30, 2012
0
0
(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete remission, ...
May 24, 2012
0
0
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...
May 2, 2012
0
0